DeepMed Research

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Radiation: Ablative Radiation Therapy
Drug: Hormone therapy or chemotherapy

First Posted Date: 2018-06-14

Last Posted Date: 2024-03-13

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 13

Registration Number: NCT03556904

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States

Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy

Not Applicable

Completed

Conditions: Gastric Cancer
Gastrointestinal Cancer
Colorectal Cancer
Stomach Cancer
Pancreatic Cancer
Esophageal Cancer

Interventions: Behavioral: MI-Walk Intervention
Behavioral: Physical Activity Education Pamphlet

First Posted Date: 2018-05-03

Last Posted Date: 2020-03-09

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 54

Registration Number: NCT03515356

Locations: 🇺🇸
The University of Michigan Northville Health Center, Northville, Michigan, United States
🇺🇸
St. Joseph Mercy Health System, Canton, Michigan, United States
🇺🇸
St. Joseph Mercy Chelsea Cancer Center, Chelsea, Michigan, United States

and more 4 locations

Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer

Phase 2

Completed

Conditions: Oropharynx Cancer

Interventions: Drug: Carboplatin
Radiation: Radiation Therapy
Drug: Paclitaxel

First Posted Date: 2018-01-30

Last Posted Date: 2025-05-22

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 91

Registration Number: NCT03416153

Locations: 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
🇺🇸
VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

Phase 2

Terminated

Conditions: Glioma
High Grade Glioma
Pontine Tumors

Interventions: Drug: Dasatinib
Drug: Everolimus

First Posted Date: 2017-11-24

Last Posted Date: 2022-10-05

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 3

Registration Number: NCT03352427

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: ARRx
Drug: Enzalutamide

First Posted Date: 2017-10-03

Last Posted Date: 2025-05-13

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 9

Registration Number: NCT03300505

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma

Phase 2

Terminated

Conditions: Urothelial Carcinoma

Interventions: Drug: Pembrolizumab
Radiation: SBRT

First Posted Date: 2017-09-19

Last Posted Date: 2021-12-15

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 6

Registration Number: NCT03287050

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma

Terminated

Conditions: Glioblastoma

First Posted Date: 2017-09-19

Last Posted Date: 2024-10-16

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 6

Registration Number: NCT03287063

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

Phase 1

Terminated

Conditions: Myelodysplastic Syndromes
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia

Interventions: Drug: Pembrolizumab

First Posted Date: 2017-09-18

Last Posted Date: 2025-05-11

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 16

Registration Number: NCT03286114

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Pembrolizumab in Combination With Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Targetable Genetic Alterations, Previously Treated With Appropriate Targeted Agents, With Progressive Disease

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2017-08-08

Last Posted Date: 2025-03-14

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 33

Registration Number: NCT03242915

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Henry Ford Cancer Institute/Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Sarah Cannon, Nashville, Tennessee, United States

and more 4 locations

Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer

Phase 2

Completed

Conditions: Urothelial Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Abraxane

First Posted Date: 2017-08-04

Last Posted Date: 2025-01-16

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 36

Registration Number: NCT03240016

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy